SAITAMA MEDICAL UNIVERSITY INTERNATIONAL MEDICAL CENTER

🇯🇵Japan

Country: 🇯🇵Japan

Ownership: Private

Established: 2007-01-01

Employees: -

Market Cap: -

Website: http://www.international.saitama-med.ac.jp

Clinical Trials

Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

Phase 2

Conditions: Cervical Cancer

Interventions: Drug: Pembrolizumab
Drug: Olaparib

First Posted Date: 2020-11-24

Last Posted Date: 2022-08-09

Lead Sponsor: Saitama Medical University International Medical Center

Target Recruit Count: 28

Registration Number: NCT04641728

Locations: 🇯🇵
Saitama Medical Uiversity International Medical Center, Hidaka, Saitama, Japan

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy